Integumen PLC Integumen wins new orders for Labskin
19 June 2017 - 4:00PM
RNS Non-Regulatory
TIDMSKIN
Integumen PLC
19 June 2017
Integumen plc
("Integumen" or "the Company")
Integumen wins new orders for Labskin, its research grade living
skin equivalent
Integumen (LSE: SKIN), the personal health care company
developing and commercialising technology and products for the
human integumentary system, is pleased to announce it has received
orders from La Prairie, Merck & Co., Inc. ("Merck"), and
Galderma S.A ("Galderma").
La Prairie
Integumen has received orders from La Prairie, the Swiss-based
beauty company with an unparalleled commitment to excellence,
luxury and the science of skincare. The brand is owned by
Beiersdorf AG, a German personal care company based in Hamburg,
manufacturing personal care products and pressure-sensitive
adhesives.
The orders are for Integumen to conduct Efficacy Trials using
Labskin as the platform, which will test certain materials in La
Prairie's range of products.
Labskin is a three-dimensional human skin equivalent (HSE) model
that resembles the discrete biological layers found in human skin.
Since the EU ban on testing of cosmetics on animals, the Company is
ideally positioned to take advantage of the fact that HSEs are
being increasingly used by developers operating in the dermatology
space such as La Prairie.
Merck
Merck, the international developer, manufacturer and distributor
of pharmaceuticals has signed an evaluation order with Integumen
for the Company's Labskin HSE model.
Galderma
Galderma is a pharmaceutical subsidiary specializing in the
research, development and marketing of dermatological treatments,
and is a wholly-owned subsidiary of Nestlé. Galderma has ordered
Labskin for testing of materials and formulations in their HQ in
Lausanne, Switzerland.
Declan Service, CEO of Integumen, said:
"We are delighted to receive these orders from such reputable
blue chip clients. With an ever-increasing focus on the human
microbiome, Labskin's advantage of being able to host bacteria in a
similar environment to that of human skin is proving to be an
attractive option for companies focussed on R&D in skincare.
While relatively small in revenue terms, these orders not only
demonstrate our ability to commercialise our products and
technologies which is what we promised to do at IPO, but also our
ability to build relationships with established companies. In
addition, we have secured our first order for Labskin under the
three-year OEM (Original Equipment Manufacturer) supply agreement
we signed with our partner in Germany, all of which is testament to
the hard work our sales and marketing team continues to do -
deliver new revenue streams."
Declan Service, + 353 (0) 87
Integumen plc CEO 770 5506
------------------------- ----------------------- ---------------------------
SPARK Advisory
Partners Limited Neil Baldwin/Sean +44 (0) 113 370
(Nominated Adviser) Wyndham-Quin 8974
------------------------- ----------------------- ---------------------------
Turner Pope Investments Ben Turner/James +44 (0) 20 3621
(TPI) Ltd Pope 4120
------------------------- ----------------------- ---------------------------
Cardew Group Shan Shan Willenbrock +44 (0) 20 7930
David Roach 0777
integumen@cardewgroup.com
------------------------- ----------------------- ---------------------------
About RNS Reach announcements
RNS Reach is an investor communication service aimed at
assisting listed and unlisted (including AIM quoted) companies to
distribute media only / non-regulatory news releases such as
marketing messages, corporate and product information into the
public domain. This contrasts with an RNS Regulatory announcement
which is required to be notified under the AIM Rules for
Companies.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAFFMITMBIBBFR
(END) Dow Jones Newswires
June 19, 2017 02:00 ET (06:00 GMT)
Integumen (LSE:SKIN)
Historical Stock Chart
From Apr 2024 to May 2024
Integumen (LSE:SKIN)
Historical Stock Chart
From May 2023 to May 2024